



## **Randomized, placebo-controlled clinical trial of donepezil for treatment of late cognitive impairment in breast cancer survivors following adjuvant chemotherapy (WF-97116)**

**Link to publication:** <https://doi-org.wake.idm.oclc.org/10.1200/JCO.23.01100>

The purpose of this study was to see if a medicine called donepezil could improve memory in women who survived breast cancer and had trouble remembering things 1-5 years after chemotherapy. Women were randomly assigned (like flipping a coin) to take donepezil or a placebo (pills that look the same but do not contain medicine) every day for 24 weeks. The staff tested memory and other thinking skills before, during, and after the treatment on each participant.

At the end of the study, about 2 out of 3 women (65%) in both groups had better memory and said their memory got better. However, there was no difference between those who took donepezil and those who took the placebo. Also, the medicine did not improve other thinking skills.

The study concluded that for these women, taking donepezil for 24 weeks did not improve memory or other brain functions when compared to taking a placebo.

